RebaEye ophthalmic solution 2% is the first in Korea and the world's second licensed treatment for Rebamipide-based dry eye syndrome, and is a new drug that combines the long-standing know-how and technology of Kukje Pharma.

Rebamipide has a mechanism to protect mucin by promoting the secretion of mucin secreted from mucous membranes such as gastric mucosa, intestinal mucosa, oral cavity, and conjunctiva. In Korea, oral solvents of the same ingredients are widely prescribed for the purpose of improving gastric ulcers and gastric mucosal lesions.

Although it has already been released and used as an eye drop in Japan since 2012, it has been pointed out that the main ingredient of "Rebamipide" is made of suspension due to its insoluble property in water, and foreign substances and irritation have been pointed out as disadvantages. Kukje Pharma's RebaEye ophthalmic solution 2% improved the unique irritation and foreign body of the suspension with its own patent (method of solubilizing Rebamipide) technology.

Kukje Pharma has been using eye drops such as hyaluronic acid, dicuaphosol, and cyclosporin as treatments for dry eyes, but expects the release of eye drops containing Rebamipide to be a new option for medical staff and dry eyes.